Skip to content
value.today

Rimidi Diabetes, Inc.

🇺🇸 Atlanta, Georgia, USAHealth CareFounded 2012
Total raised
$15 M
4 rounds on record
Latest round
$2 M
Jan 2024
First round on record
Oct 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Rimidi Diabetes, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2024$2 MNo. 4$2 to $10 million

Rimidi Diabetes, Inc.: Raise no. 4, Jan 2024

Investors in this round

1 investor had bought by the notice of Jan 24, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jennifer Ide · Executive Officer
  • Lucienne Ide · Executive Officer, Director
  • Kevin Bunker · Director
  • Mark Braunstein · Director
  • R. William, III Ide · Director
  • Robert Turner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lucienne Ide, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 24, 2024. Read the notice at the SEC.

debt, optionsSEC
Dec 2022$5 MNo. 3$2 to $10 million

Rimidi Diabetes, Inc.: Raise no. 3, Dec 2022

Investors in this round

1 investor had bought by the notice of Jan 12, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jennifer Marie Ide · Executive Officer
  • Kirk Marie Barnes · Executive Officer
  • Lucienne Marie Ide · Executive Officer, Director
  • Mark Marie Braunstein · Director
  • Mark Marie Mlotek · Director
  • R. William, III Marie Ide · Director
  • Robert Marie Turner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lucienne Ide, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 12, 2023. Read the notice at the SEC.

equitySEC
Jul 2018$7 MNo. 2$2 to $10 million

Rimidi Diabetes, Inc.: Raise no. 2, Jul 2018

Investors in this round

14 investors had bought by the notice of Jul 17, 2018: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher McIlvoy · Executive Officer
  • Jennifer Ide · Executive Officer
  • Joshua Claman · Executive Officer
  • Lucienne Ide · Executive Officer, Director
  • Bob Bozeman · Director
  • R. William Ide III · Director
  • Robert Turner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Josh Claman, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 17, 2018. Read the notice at the SEC.

equitySEC
Oct 2014$1 MNo. 1Under $2 million

Rimidi Diabetes, Inc.: Raise no. 1, Oct 2014

Investors in this round

14 investors had bought by the notice of Oct 24, 2014: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris Marie McIlvoy · Executive Officer
  • Jennifer Marie Ide · Executive Officer
  • Lucienne Marie Ide · Executive Officer, Director
  • R. William, III Marie Ide · Executive Officer, Director
  • Robert Marie DeHaven · Executive Officer
  • Bob Marie Bozeman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lucienne Ide, President. Source: SEC Form D, newest notice filed Oct 24, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Rimidi Diabetes, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2024).

    SEC Form D · Jan 2024

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jan 2024

That is all the official record says: Rimidi Diabetes, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Rimidi Diabetes, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Rimidi Diabetes, Inc.
NameRoleNamed in
Jennifer IdeExecutive officerJan 2024
Lucienne IdeExecutive officerJan 2024
Jennifer Marie IdeExecutive officerJan 2023
Kirk Marie BarnesExecutive officerJan 2023
Lucienne Marie IdeExecutive officerJan 2023
Christopher McIlvoyExecutive officerJul 2018
Joshua ClamanExecutive officerJul 2018
Chris Marie McIlvoyExecutive officerOct 2014
R. William, III Marie IdeExecutive officerOct 2014
Robert Marie DeHavenExecutive officerOct 2014
Kevin BunkerDirectorJan 2024
Lucienne IdeDirectorJan 2024
Mark BraunsteinDirectorJan 2024
R. William, III IdeDirectorJan 2024
Robert TurnerDirectorJan 2024
Lucienne Marie IdeDirectorJan 2023
Mark Marie BraunsteinDirectorJan 2023
Mark Marie MlotekDirectorJan 2023
R. William, III Marie IdeDirectorJan 2023
Robert Marie TurnerDirectorJan 2023
Bob BozemanDirectorJul 2018
R. William Ide IIIDirectorJul 2018
Bob Marie BozemanDirectorOct 2014